1.8.2.post0 Label Studio annotation … ← Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD Optimizing LLMs From a Dataset Perspective →